Recent Quotes (30 days)

You have no recent quotes
chg | %

Arch Biopartners, Inc.  

(Public, CNSX:ACH)   Watch this stock  
Find more results for ACH
0.125
-0.005 (-3.85%)
Apr 17 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range 0.12 - 0.12
52 week 0.00 - 0.37
Open 0.12
Vol. 60,000.00
Mkt cap 6.03M
P/E     -
Div/yield     -
EPS 0.00
Shares 48.26M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -560.56% -290.80%
Return on average equity - -
CDP Score - -

Address

27 ST. CLAIR AVENUE EAST PO Box 305
TORONTO, ON M4T 2M5
Canada
+1-647-4287031 (Phone)
+1-905-7704454 (Fax)

Website links

Description

Arch Biopartners Inc., is a Canada-based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. As of September 30, 2012, Novel treatments for brain tumours (the focus of Arch Cancer Therapeutics Ltd.); Novel treatments for chronic kidney and bowel diseases caused by non-infectious inflammation; (the focus of Arch Biotech Inc.), and Binding of peptides to solid surfaces ( the focus of Arch Biophysics). The Company has focused product development around three compounds: ABP-0904, ABP-0912 and ABP-0918. The Company´┐Żs technology includes Arch Biophysics Ltd, Arch Biotech (or Arch Inflammation) Technology Developments, Arch Cancer Therapeutics Technology Developments and Colorado Cancer Therapeutics Technology Developments.

Officers and directors

Jerome F. Mcelroy Chairman of the Board
Richard Muruve President, Chief Executive Officer, Director
Claude Allary Interim Director
Andrew Bishop Director
Conor M. Gunne Independent Director
Richard Rossman M.D. Independent Director